BBIO vs DD · rev $221.9M vs P/E 127, rev $12.39B
BridgeBio Pharma Inc (BBIO) versus Dupont De Nemours Inc (DD) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Dupont De Nemours Inc (DD) is a specialty chemicals company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported DD revenue for 2024-12-31 was $12.39B. Net income was $738.0M. Revenue was up 2.6% from 2023-12-31 to 2024-12-31. DD currently screens at market cap $19.61B and trailing P/E 127.4.
BBIO currently screens at market cap $13.24B. DD currently screens at market cap $19.61B and trailing P/E 127.4.
Not investment advice. Open the BBIO and DD stock pages for the full models.
Not investment advice.